Lonza to build capabilities for drug product development services
Capabilities will focus on parenteral dosage forms for biologics, drug conjugates, peptides and small molecules for products for injection or infusion.
Lonza has announced that its Pharma&Biotech segment is expanding its footprint to offer customers a complete portfolio of development and manufacturing services for clinical outsourcing requirements by entering into Drug Product Services. This new service offering is part of Lonza’s drive to enable customers to meet some of the greatest challenges in patient treatment. These drug product services will focus on parenteral dosage forms, including products for injection and infusion for intravenous, subcutaneous, intraocular and other routes of parenteral administration. Services will include options for monoclonal antibodies, other biologics, drug conjugates, peptides and small molecules that require a parenteral dosage form.
Drug Product Services will be offered in the fourth quarter of 2016 from laboratories based in Basel (CH), with an initial focus on Formulation Development and Drug Product Analytical Development and Quality Control. Specialized services will also be available for customers, such as particulate identification, characterization and quantification, excipient and surfactant characterization, extractables & leachables assessment and testing of container closure integrity. Drug Product manufacturing capabilities for preclinical and clinical use (cGMP) will be available in late 2016.
Heading the Drug Product Business is Prof. Dr. Hanns-Christian Mahler, who for 10 years led the departments of Pharmaceutical Development & Supplies and Formulation R&D Biologics for Roche. His extensive work experience in this field includes early- and late-stage Formulation Development, primary packaging and device development, Drug Product process development, process characterization and validation, protein analytics and Drug Product cGMP manufacturing. He also has a strong track record in successful regulatory filings, including INDs/IMPDs and BLAs/MAAs.
Prof. Mahler is building a Drug Product Services team that has exceptional industry experience in Formulation Development, Drug Product process development, Drug Product Analytics and cGMP manufacturing. This new team will provide best-in-class services for parenteral dosage forms for several drug classes.
“Expansion of our portfolio into Drug Product Services fits well with our existing and future customers’ needs and is an important step in becoming a one-stop-shop for all clinical outsourcing requirements,” said Marc Funk, COO of Lonza. “Beginning with our GS and XS Gene Expression Technologies, continuing with cell line construction, process and analytical development through to clinical supply, our new Drug Product Services team enables Lonza to provide world-class services.“
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance